- Daiichi Sankyo Co.
, which are
pharmaceutical companies based inJapan . Its main offices are located inChūō, Tokyo .Acquisitions
On
June 10 ,2008 , Daiichi Sankyo Co., agreed to take a majority (35%) stake in Indian generic drug maker Ranbaxy, with a deal valued at about $4.6 billion. Ranbaxy's Malvinder Singh will remain CEO after the transaction. [ [http://brandfaqs.blogspot.com/search/label/Ranbaxy Daiichi to get 35% stake in Ranbaxy] ] [ [http://brandfaqs.blogspot.com/2008/06/ranbaxy-promoters-to-sell-stake-to.html The Brand Blog: Ranbaxy promoters to sell stake to Japan's Daiichi ] ] Also in June 2008, the company expressed intent to acquireU3 Pharma , which would contribute a therapeutic anti-HER3 antibody to the company's anticancer portfolio. [cite news | author=staff
title=Daiichi Sankyo Intends to Purchase U3 Pharma for Roughly $236M | url= | format=print
work=Genetic Engineering & Biotechnology News | publisher=Mary Ann Liebert, Inc. | page=8 | date=2008-06-15
accessdate=2008-07-06 ]Major products of Daiichi Sankyo Group
ankyo
*Benicar(
olmesartan medoxomil )
*Mevalotin (pravastatin )
*Loxonin (loxoprofen )
*Olmetec (olmesartan )
*Captopril
*Zantac (ranitidine )
*WelChol (colesevelam HCl )Daiichi Pharmaceutical
*Cravit (
levofloxacin )
*Evoxac (cevimeline )
*FloxinOtic (ofloxacin )Notes
External links
* [http://www.daiichisankyo.co.jp/index.html Daiichi Sankyo official site]
Wikimedia Foundation. 2010.